Multinucleate Cell Angiohistiocytoma Treated With a 650 Microsecond Nd:YAG 1064 Laser

Abstract

through at any given time. 1 These microchannels additionally limit the depth to which the PLLA can penetrate, which likely affects the immune system's response and subsequent granulomatous processes. In contrast to typical injections using focal volumes of PLLA, LADD distributes very small volumes of PLLA throughout the treatment area. There are major differences in the amount of PLLA that is ultimately placed in the dermis.Although limited by its retrospective and single-center design, our study demonstrates the safety of fractional ablative laser-assisted delivery of topical PLLA. However, additional prospective, controlled studies would be beneficial to further confirm these results. Physicians who may be apprehensive of applying topical PLLA after ablative laser treatment should be reassured by these data.

Treatment Options for Multinucleate Cell Angiohistiocytoma: A Case Series and Review of the Literature

“…Surgery, 3 cryotherapy, 12 CO2 laser, 13,14 and vascular lasers 15 -22 have been successfully used. Other therapies such as topical or intralesional corticosteroids did not show effectiveness.…”

“…Therapy intervention is indicated if MCAH causes itching or an esthetic problem. Surgery, 3 cryotherapy, 12 CO2 laser, 13,14 and vascular lasers [15][16][17][18][19][20][21][22] have been successfully used. Other therapies such as topical or intralesional corticosteroids did not show effectiveness.…”

“…23 In 1995, Kopera et al published the first two patients with MCAH treated with argon laser. 15 Since then, some case reports of MCAH treated with other lasers have been published: ablative CO2 laser, 13,14 IPL, 3,6 and more recently PDL, 17,18 Nd:YAG [19][20][21] and potassium-titanyl-phosphate (KTP) laser in combination with intralesional corticosteroids. 22 Vascular lasers are useful in treating MCAH since they have their target in the oxyhemoglobin inside vessels.…”